We are now in the era of “Personalized Medicine”

In general there are four types of lung cancer.

In order to make a diagnosis “Tissue is always the issue”!

(For a detailed explaination of lung biopsy please see the Navigational Bronchoscopy page.)

With the expanding use of Low Dose Lung Screening CT Scans to help find early lung cancers, we also find many small nodules that are of varying degrees of suspicion. In addition lung nodules are often found on X-rays for other reasons, like Cardiac Scoring scans.

All of them can not and should not be biopsied. That decision is best decided by a team of specialists reviewing your case, often with a multidisciplinary thoracic oncology program. This can often present a dilemma as to wether to put a patient through an invasive biopsy procedure or wait and see if the small nodule grows, or if the first biopsy is non-diagnostic do we wait or perform additional biopsies. The answer is always more data needed…….can we learn more about your lung nodule before we get invasive?


Utilizing all the technology at our disposal to help find lung cancer early!


This is a simple blood test that is designed to look for specific cell free tumor mutated DNA or certain proteins associated with lung cancer that are shed and circulating in the bloodstream.

This test does NOT tell you the major type of lung cancer(Adeno, Squamous or Large cell) you have but is focused on DNA specific mutations that occur in all of them.

A “liquid biopsy” may be helpful to find diagnose cancer at an early stage or predict how recurrect or advanced lung cancer will respond to chemotherapy.

The FDA approved liquid biopsy measures in 2015 and this ability to analyze this data and make recommendations upon lung cancer treatment grows daily.

We have been performing Biodesix Liquid Biopsy on selected patients for the last year to add to our diagnostic evaluation and correlate with pathological biomarker testing of surgical specimens.

Genetic mutation biomarkers can also analyzed on the surgically removed specimens, but the VeriStrat molecular profiling analysis must be done from blood prior to surgical or adjuvant therapy.

If the VeriStrat test is poor it reflects a more aggresive cancer and consideration for advanced treatment or perhaps a clinical trial

We feel this additional level of non-invasive testing is very helpful for Pulmonologists, Oncologists and Thoracic Surgeons involved in Lung screening and Lung nodule programs

This information is an adjunct to the main biopsy techniques.

Results are back within a few days.


For more information please go to: http://www.biodesix.com/


We are also investigating another genomic classifier RNA test from Veracyte: Percepta Bronchial Swab.

This minimally invasive test analyzes upper respiratory epithelial cells via messenger-RNA based assay measuring the expression of 23 genes, including 17 cancer genes in high risk smokers.

Like a Liquid Biopsy it can add greatly to the mounting evidence that a cancer may exsist in your lungs.

This helps decide how aggresively your Thoracic team needs to persue a diagnosis versus watching and waiting.

Done during the start of any bronchoscopy procedure.

This brush is rubbed along the upper airway collecting cells.

If the biopsies from a bronchoscopy are not diagnostic but the Percepta Swab is “high risk” then more invasive testing should most likely be done, so that a cancer is not missed.

For more information please go to: Veracyte.com

Let’s use the best technology to put the most information possible in your hands so together we can do the right thing to find early lung cancer and cure it!

Are you brave enough to get a Low Dose Lung Screening CT scan?

See your primary care doctor to see if you qualify- knowledge is power.

Sieze your lung……. Seize your life!